Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zet
Zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25. This benefit occurred with a 53% mean reduction of background corticosteroid use.ORRs increased to 94.1% at Week 29 and 88.2% at Week 37 during the safety fol...